NovoArc Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Grant

  • Investors
  • 4

NovoArc General Information

Description

Developer of specialized lipid-based components designed for use in drug formulation and delivery applications. The company utilizes a proprietary technology platform to produce highly pure, semi-synthetic tetraether lipids inspired by extremophilic microorganisms, enabling pharmaceutical developers to improve the protection, delivery efficiency and overall effectiveness of active pharmaceutical ingredients.

Contact Information

Website
www.novoarc.at
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Pottendorfer Straße 23-25, 4, 4-1
  • Vienna, 1120
  • Austria
+43 01
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • Pottendorfer Straße 23-25, 4, 4-1
  • Vienna, 1120
  • Austria
+43 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NovoArc Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 01-Jan-2022 Completed Generating Revenue
5. Angel (individual) Completed Generating Revenue
4. Grant Completed Generating Revenue
3. Grant 01-Jan-2019 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2019 Completed Generating Revenue
1. University Spin-Out Completed Generating Revenue
To view NovoArc’s complete valuation and funding history, request access »

NovoArc Patents

NovoArc Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024330157-A1 Lipid nanoparticle with nucleic acid cargo and ionizable lipid Pending 01-Sep-2023
EP-4770622-A1 Lipid nanoparticle with nucleic acid cargo and ionizable lipid Pending 01-Sep-2023
WO-2025046121-A1 Lipid nanoparticle with nucleic acid cargo and ionizable lipid Inactive 01-Sep-2023
AU-2023347022-A1 Lipid nanoparticle with nucleic acid cargo Pending 21-Sep-2022
EP-4342460-A1 Lipid nanoparticle with nucleic acid cargo Inactive 21-Sep-2022 A61K9/5123
To view NovoArc’s complete patent history, request access »

NovoArc Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NovoArc Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Austria Wirtschaftsservice Venture Capital Minority
Österreichische Forschungsförderungsgesellschaft Government
TU Wien Innovation Incubation Center Accelerator/Incubator Minority
TU Wien University
To view NovoArc’s complete investors history, request access »

NovoArc FAQs

  • When was NovoArc founded?

    NovoArc was founded in 2021.

  • Where is NovoArc headquartered?

    NovoArc is headquartered in Vienna, Austria.

  • What is the size of NovoArc?

    NovoArc has 17 total employees.

  • What industry is NovoArc in?

    NovoArc’s primary industry is Drug Delivery.

  • Is NovoArc a private or public company?

    NovoArc is a Private company.

  • What is NovoArc’s current revenue?

    The current revenue for NovoArc is .

  • Who are NovoArc’s investors?

    Austria Wirtschaftsservice, Österreichische Forschungsförderungsgesellschaft, TU Wien Innovation Incubation Center, and TU Wien have invested in NovoArc.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process